DarioHealth (DRIO)
(Delayed Data from NSDQ)
$1.16 USD
+0.01 (0.87%)
Updated Apr 19, 2024 04:00 PM ET
After-Market: $1.17 +0.01 (0.86%) 5:08 PM ET
3-Hold of 5 3
D Value D Growth A Momentum D VGM
Income Statements
Fiscal Year end for DarioHealth Corp falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 20 | 28 | 21 | 8 | 8 |
Cost Of Goods | 14 | 18 | 17 | 5 | 5 |
Gross Profit | 6 | 10 | 4 | 3 | 3 |
Selling & Adminstrative & Depr. & Amort Expenses | 62 | 66 | 80 | 32 | 20 |
Income After Depreciation & Amortization | -56 | -57 | -77 | -30 | -18 |
Non-Operating Income | 0 | 0 | 0 | 0 | 0 |
Interest Expense | 3 | 5 | 0 | 0 | 0 |
Pretax Income | -59 | -62 | -77 | -29 | -18 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -59 | -62 | -77 | -29 | -18 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -59 | -62 | -77 | -29 | -18 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -51 | -52 | -72 | -30 | -18 |
Depreciation & Amortization (Cash Flow) | 5 | 5 | 5 | 0 | 0 |
Income After Depreciation & Amortization | -56 | -57 | -77 | -30 | -18 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 28.37 | 23.64 | 16.59 | 5.96 | 2.27 |
Diluted EPS Before Non-Recurring Items | -1.93 | -2.54 | -4.07 | -4.01 | -8.00 |
Diluted Net EPS (GAAP) | 1.93 | -2.54 | -4.07 | -4.01 | -8.00 |
Fiscal Year end for DarioHealth Corp falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 3.62 | 3.52 | 6.15 | 7.07 |
Cost Of Goods | NA | 3.48 | 2.91 | 4.08 | 3.90 |
Gross Profit | NA | 0.13 | 0.61 | 2.07 | 3.17 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 14.35 | 16.16 | 16.09 | 15.58 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -14.22 | -15.55 | -14.02 | -12.41 |
Non-Operating Income | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Interest Expense | NA | 0.01 | 0.19 | 2.57 | 0.42 |
Pretax Income | NA | -14.22 | -15.73 | -16.59 | -12.83 |
Income Taxes | NA | 0.06 | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -14.29 | -15.73 | -16.59 | -12.83 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -14.29 | -15.73 | -16.59 | -12.83 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 37.82 | 28.82 | 28.19 | 27.57 |
Diluted EPS Before Non-Recurring Items | NA | -0.41 | -0.49 | -0.58 | 0.45 |
Diluted Net EPS (GAAP) | NA | 3.45 | -0.49 | -0.58 | -0.45 |